groups, GSRS analysis showed a significant improvement of the overall GSRS score at the assessment of eradication efficacy, compared to baseline; there was no difference between the groups. Conclusion: With this H. pylori eradication regimen, there was no difference in the cure rates and QoL associated with PPI pretreatment.
Does Pretreatment with Lansoprazole
Since the discovery of Helicobacter pylori in the gastric mucosa, the relationship between H. pylori and peptic ulcers has been documented in numerous studies [1] . H. pylori eradication contributes significantly to the healing of peptic ulcers, prevents relapse of the ulcers and improves the symptoms [2, 3] .
Labenz et al. [4] reported that initial treatment with omeprazole followed by combined amoxicillin plus omeprazole treatment yielded disappointing eradication rates. However, it was subsequently reported that initial treatment with a proton pump inhibitor (PPI), either
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The aim of this study was to investigate whether there was a difference in the H. pylori cure rates between eradication with and without PPI pretreatment. Furthermore, other studies indicated that the gastrointestinal symptoms of peptic ulcers greatly decreased the quality of life (QoL) of patients [10] [11] [12] . Therefore, the effect of H. pylori eradication and ulcer healing on the QoL of the patients was investigated using questionnaires. In addition, the QoL of the patients was compared between those with versus those without PPI pretreatment.
Patients and Methods

Study Population
This randomized controlled trial (RCT) was conducted in Okayama University Hospital, Okayama, and 11 affiliated hospitals in Japan, between October 2004 and February 2007. The multicentre RCT enrolled patients who had been diagnosed with a gastric ulcer and/or duodenal ulcer by endoscopy as well as a verified H. pylori infection. Two biopsies (one from the antrum and one from the corpus) were taken to test for urease activity, histology and culture to detect H. pylori .
Patients were excluded if they were less than 18 years of age or older than 75 years; were on continuous treatment with nonsteroidal anti-inflammatory drugs; had severe heart, renal or liver disease, malignancy or other severe diseases; or were allergic to the study protocol drugs. Patients were also excluded in cases of pregnancy, gastrectomy or prior H. pylori eradication before enrolment.
This study was approved by the Institutional Review Board of each hospital, and all patients received information about the objectives, significance of the study and possible side effects, and gave their written informed consent. Protocol design and flow of the study. Treatment with the PPI (lansoprazole) alone was administered for 8 weeks in patients with a gastric ulcer and for 6 weeks in those with a duodenal ulcer. The GSRS questionnaire was completed at each visit. A time span of at least 4 weeks without administration of any PPI was required between treatment completion and the assessment of eradication efficacy. GSRS = Gastrointestinal Symptom Rating Scale.
Investigation
Patients were assigned to receive one of two therapeutic regimens in this RCT, random assignment in each center was performed by using computer-generated randomization lists, which was provided from our hospital ( fig. 1 ) . Patients in group A were pretreated with lansoprazole (30 mg) administrated orally once daily, followed by an eradication regimen consisting of lansoprazole (30 mg), amoxicillin (750 mg) and clarithromycin (200 mg) twice daily for 1 week. Patients in group B received the same eradication regimen used for group A without the pretreatment, followed by lansoprazole (30 mg) administrated orally once daily. In both groups, the treatment with lansoprazole alone (either before or after eradication) was administered for 8 weeks in patients with gastric ulcer and for 6 weeks in those with duodenal ulcer. The efficacy of eradication was assessed at least 4 weeks after the completion of all treatments. During this post-treatment time span, patients did not receive any PPI, to avoid the possibility of falsenegative results at the assessment of H. pylori eradication [13] . But we did not prohibit the administration of mucosa-protective agents or of anti-ulcer drugs excluding PPIs. It was considered to be successful if the urea breath test and histological examination all showed negative results. In the urea breath test, patients provided a baseline expiratory breath sample, then rinsed out their mouths and ingested 100 mg of 13 C-urea, and another expiratory breath sample was collected 20 min later. If the difference between the 13 CO 2 to 12 CO 2 ratio at baseline and the ratio after 20 min was ! 2.5‰, the test result was assessed as negative [14] .
Evaluation of Gastrointestinal Symptoms
The Gastrointestinal Symptom Rating Scale (GSRS) is a specific 15-item questionnaire used to assess the QoL of patients with gastrointestinal symptoms [15] . Patients are asked to numerically score their subjective symptoms on a Likert-type scale of 1-7. The sum of the scores for all 15 items is regarded as the total GSRS score. Because each of the 15 questions can be scored from 1 to 7, the minimum total score obtainable is 15, and the maximum total score is 105. This total is then divided by 15 to obtain the 'overall' GSRS score, from a minimum of 1 to a maximum overall score of 7. The higher the overall score, the more severe the symptoms [10] .
In group A, results from the questionnaires were recorded at enrolment, after PPI pretreatment, after eradication treatment and at assessment of eradication efficacy ( fig. 1 ) . In group B, the questionnaires were completed at enrolment, after eradication treatment, after PPI treatment and at assessment of eradication efficacy. As a result, four questionnaires per patient were to be completed in each treatment group.
Statistical Methods
To compare the baseline characteristics of the two groups, the Student's t test and 2 test were used. Factors potentially associated with successful eradication were investigated using unadjusted and adjusted logistic regression analyses. For assessment of GSRS, we used Mann-Whitney test and Wilcoxon signed-ranks test. A statistically significant level was defined as p ! 0.05. All analyses were performed using the SAS software program, version 8 (SAS Institute Inc., Cary, N.C., USA). Sample size was calculated based on the Dunnett-Gent noninferiority test [16] . We assumed that the eradication rate would be 83.0% for the group without pretreatment and 90.0% for the group with pretreatment [17] . More than 50 patients were needed per group, based on a 5% significance level and statistical power of 80% with the use of a one-sided noninferiority test.
Results
Study Population
A total of 116 patients were enrolled in this study. The basic characteristics of the two groups (group A: n = 57; group B: n = 59) were comparable, without significant differences ( table 1 ). A total of 106 participants completed the protocol (group A: n = 53; group B: n = 53). Ten patients were excluded from the per-protocol (PP) analysis: seven did not return to the hospital for assessment of H. pylori eradication, two refused eradication treatment, and one withdrew his consent ( fig. 1 ) .
Eradication Rates and Side Effects
An intention-to-treat (ITT) analysis showed that H. pylori was eradicated in 45 of 57 patients (78.9%) in group A and in 46 of 59 (78.0%) in group B. Based on a PP analysis, H. pylori was eradicated in 45 of 53 patients (84.9%) in group A and in 46 of 53 (86.8%) in group B. There was no significant between-group difference in the cure rates, according to both analyses ( table 2 ) . At the time of assessment of eradication, all patients excluding two in group B had gastric and duodenal ulcer scars. Those two patients had gastric ulcers in the healing stage, but their eradication therapy was successful. Then their ulcers were cured after adequate therapy. The most frequent side effects were soft stool (15%), followed by diarrhea (11%), oral discomfort (7%), constipation (4%), abdominal distension (4%), nausea (3%), abdominal discomfort (2%), flatulence (1%), eruption (1%) and abdominal pain (1%). 18 patients (32%) in group A and 24 patients (41%) in group B complained of these side effects. However, these adverse effects were all mild and did not need any treatment.
Sex, age, smoking, ulcer location and PPI pretreatment were investigated as factors potentially associated with successful eradication, using unadjusted and adjusted logistic regression analyses, but none of these factors were associated with successful eradication. These data are not shown.
Quality of Life
Of the enrolled patients, 81 completed the GSRS questionnaires so were included in the evaluation of QoL. The GSRS analyses at enrolment and at the assessment of eradication efficacy indicated that there was no significant difference between the two patient groups. In each group, significant improvements of the GSRS scores were observed at the assessment of eradication efficacy, compared to baseline (p ! 0.001) (data not shown).
Discussion
When treating patients with a peptic ulcer, antacid drugs are frequently administered, including PPIs, to initially treat the ulcer and gastrointestinal symptoms. However, some reviews have reported that PPI pretreatment before H. pylori eradication may actually decrease the eradication rate [4, 18] . The authors theorized that PPIs might induce coccoid-persistent forms of H. pylori in a direct or indirect manner and that H. pylori exposed to PPIs were in a less active, dormant state and therefore less vulnerable to the actions of antibiotics. Other studies have reported that pretreatment with a PPI did not reduce the rate of eradication [5] [6] [7] 17] . Janssen et al. [8] have reported the results of a meta-analysis indicating that pretreatment did not influence eradication, but this metaanalysis did not include the regimen recommended in Japan (lansoprazole, amoxicillin and clarithromycin). Our prospective study was the first to investigate the influence of pretreatment on H. pylori eradication performed with this therapeutic regimen of lansoprazole, amoxicillin and clarithromycin. There was no statistically significant difference in the cure rate between patients with pretreatment and those without pretreatment. Therefore, pretreatment with lansoprazole did not decrease the efficacy of H. pylori eradication. The cure rates in this study's ITT and PP analyses were consistent with those of other reports [8] .
In the present study, none of the potentially prognostic factors analyzed were statistically associated with the treatment outcome. Recently, a small sustained increase in the rate of resistance to clarithromycin has been noted with increased usage [19] . This resistance has been recognized as an important factor influencing the eradication rates [20] . On the other hand, Furuta et al. [21] reported that CYP2C19 genotype status was significantly associated with successful eradication of H. pylori using triple therapy with omeprazole or lansoprazole, clarithromycin and amoxicillin. Regrettably, the clarithromycin-sensitivity test and CYP2C19 genotyping of patients could not be performed during this study. It is possible that both these factors could have influenced the results, but the effect would be minimized in the comparison of the two therapeutic regimens because the patients were randomly assigned to treatment.
In the evaluation of different treatment alternatives, it is necessary to focus not only on the treatment outcome, but also on the symptomatic improvement of the patients. Because upper gastrointestinal disorders negatively affect the QoL of patients, the evaluation of QoL in the treatment of peptic ulcers is very important. The validity of the GSRS and other questionnaires for QoL evaluation in upper gastrointestinal disorders and in H. pylori eradication has been documented [10, 11, 22, 23] . It is essential that disease-specific assessment instruments for gastrointestinal disorders (like the GSRS) continue to be evaluated for reliability and validity [24] . There are reports indicating that successful eradication of H. pylori using specific therapeutic regimens (e.g. amoxicillin, clarithromycin and lansoprazole; or amoxicillin, metronidazole and lansoprazole) improved the QoL of patients [10, 11] . Similar results were obtained in the present study, which also evaluated the change in the GSRS with and without PPI pretreatment.
In conclusion, this study indicated that when treating H. pylori infection with lansoprazole, amoxicillin and clarithromycin, there was no significant difference between therapeutic regimens with versus without PPI pretreatment, based on the cure rates and QoL. Successful eradication led to a significant improvement in the QoL of patients.
